Zinc and copper inhibit nerve growth factor-mediated protection from oxidative stress-induced apoptosis
These results demonstrate that Zn2+ and Cu2+ can selectively inhibit NGF-mediated resistance to an oxidative stress, and have significant implications for neuronal function under both physiological and pathological (e.g. cerebral ischemia) conditions.
Plasma extracellular superoxide dismutase levels in an Australian population with coronary artery disease
http://atvb.ahajournals.org/content/18/12/1915.long
In summary, our study shows that in patients requiring investigation by coronary angiography, plasma EC-SOD is lower in men than in women; that smoking is associated with depressed levels in both sexes; and that low levels are independently associated with a history of MI. Our present findings are consistent with EC-SOD’s being associated with a reduced coronary risk.
Spinal bone loss in postmenopausal women supplemented with calcium and trace minerals
http://jn.nutrition.org/content/124/7/1060.long
The effects of calcium supplementation (as calcium citrate malate, 1000 mg elemental Ca/d) with and without the addition of zinc (15.0 mg/d), manganese (5.0 mg/d) and copper (2.5 mg/d) on spinal bone loss (L2-L4 vertebrae) was evaluated in healthy older postmenopausal women (n = 59, mean age 66 y) in a 2-y, double-blind, placebo-controlled trial.
The second phase clinical observation of anti-radiation effect by superoxide dismutase
https://www.ncbi.nlm.nih.gov/pubmed/10681768
Multiple center randomized controlled double blind clinical trait was conducted to evaluate the anti-radiotherapy effect by SOD (produced by Hunan Biochemical Work) in 159 patients. Injection of 4000U SOD immediately after receiving radiotherapy significantly reduced the occurrence rate of skin, oral mucosa, pelvic visceral and systemic adverse reaction, only the reduction of leukopenia did not reach the statistical significant level. No adverse effect of SOD injection was observed. The results suggest that SOD is a safe and effective agent to attenuate the radiotherapy reactions.
Determination of Serum Trace Elements (Zn, Cu, and Fe) in Pakistani Patients with Rheumatoid Arthritis.
https://www.ncbi.nlm.nih.gov/pubmed/27239678
Trace elements act as cofactors for most of the enzymes, and their deficiency is associated with many untoward effects on human health.
Serum Trace Element Concentrations in Rheumatoid Arthritis.
https://www.ncbi.nlm.nih.gov/pubmed/26450515
Low serum concentrations of Zn and Se, and high serum Cu concentrations may be associated with the presence of RA or be a consequence of this condition.
Trace element status may therefore be involved in the pathogenesis of RA or be affected by the disease activity of this chronic inflammatory condition.
Inadequate antioxidant nutrient intake and altered plasma antioxidant status of rheumatoid arthritis patients
https://www.ncbi.nlm.nih.gov/pubmed/12897046
Elevated free radical generation in inflamed joints and impaired antioxidant system have been implicated in rheumatoid arthritis (RA). The present study was performed to evaluate dietary nutrient intake and plasma oxidant/antioxidant status in RA patients. The activity of plasma SOD and GPx in patients was significantly lower than that in control subjects. These results suggest proper antioxidant nutrient intake management may reduce free radical generation and improve antioxidant status in RA patients.
Use of superoxide dismutase (SOD) in patients with temporomandibular joint dysfunction - a preliminary study
https://www.ncbi.nlm.nih.gov/pubmed/7890991
The aim of this preliminary study was to investigate and assess the effect of intra-articular injection of superoxide dismutase (SOD) in patients with temporomandibular joint (TMJ) dysfunction who had not responded to conservative therapy in a first study. Thirty joints in 29 patients were studied. The results showed that intra-articular injection of superoxide dismutase was effective in 25 joints (83%). It was concluded that intra-articular injection of superoxide dismutase may be an alternative therapy for patients with TMJ dysfunction who fail to respond to conservative treatment.
Safety and pharmacokinetics of multiple doses of recombinant human CuZn superoxide dismutase
http://pediatrics.aappublications.org/content/100/1/24
Safety and pharmacokinetics of multiple doses of recombinant human CuZn superoxide dismutase administered intratracheally to premature neonates with respiratory distress syndrome. The data indicates that multiple IT doses of rhSOD increase the concentration and activity of the enzyme in serum, TA and urine, reduce TA lung injury markers and are well-tolerated. Further clinical trials examining the efficacy of rhSOD in the prevention of BPD are warranted.
Serum copper and zinc levels in individuals with autism spectrum disorders
These results suggested an association between serum levels of Zn and Cu and ASD among Chinese patients,and the Zn/Cu ratio could be considered a biomarker of ASD. The ability of Zn to upregulate MT gene expression and reduce toxicity from heavy metal exposure suggests that the provision of Zn to children with ASDs may be an important component of a treatment protocol. Much more research, however, is necessary, to draw conclusions on the connection between Zn and Cu and ASD
Phase II trial of copper zinc superoxide dismutase (CuZn SOD) in the treatment of Crohn's disease
https://www.ncbi.nlm.nih.gov/pubmed/2060833
Bovine Cu Zn SOD was used during an 8 year period as an anti inflammatory drug in 26 patients with severe Crohn's disease (CDAI 300) usually after failure of corticotherapy or when this drug was discontinued because of side effects or infection. This was a phase II trial during which doses routes of administration and concomitant therapies were progressively modified. We obtained 73% good short term responses (judged upon CDAI and anatomic healing) and 82% positive results on long term evolution (the criteria were: i CDAI lower than 100 in between relapses, ii complete healing or notable improvement of lesions, iii no surgery needed, iv return to work. The acceptability was excellent with the free enzyme. Since the above described experience, published in Free Radical Biology and Medicine (1989, 7: 145-151), we used always the same treatment schedule (SOD 8 mg/day associated with Desferroxamine--500 mg subcutaneous every 2 days). The follow-up during the 87-89 period showed that 12 are in good health without any relapse, 9 experienced one or more relapses, and showed good responses upon resumption of treatment, 5 failed to respond to treatment, all part of the initial group on which SOD treatment had already failed, and among whom 3 were lost for follow-up before 1987, and two others took up another SOD treatment which also failed. 3 new patients (2 females, 1 male) were treated since then, and all 3 had positive results (one with disappearance of ileocoecal mass). The efficacy of SOD as an anti inflammatory drug in Crohn's disease needs to be confirmed by controlled trials.